Trials / Completed
CompletedNCT01234558
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLYX-13 | single IV dose |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-06-01
- Completion
- 2012-07-01
- First posted
- 2010-11-04
- Last updated
- 2012-09-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01234558. Inclusion in this directory is not an endorsement.